Publications by authors named "Thomas Goddemeier"

Claim this Profile
A
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Howard A Burris, Jordan Berlin, Tobias Arkenau, Gregory M Cote, Martijn P Lolkema, Thomas Goddemeier

Br J Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical implementation of the partial ordering continual reassessment method in a Phase I combination-schedule dose-finding trial.
Pavel Mozgunov, Thomas Jaki, Ioannis Gounaris, Thomas Goddemeier, Anja Victor

Stat Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Melinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, Mark Middleton, Simon R Lord, Thomas Goddemeier

NPJ Breast Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Ruth Plummer, Emma Dean, Hendrik-Tobias Arkenau, Charles Redfern, Alexander I Spira, Thomas Goddemeier

Lung Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors.
Takashi Kojima, Kentaro Yamazaki, Ken Kato, Kei Muro, Hiroki Hara, Thomas Goddemeier

Cancer Sci· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Jean-Pascal Machiels, Marie-Christine Kaminsky, Ulrich Keller, Tim H Brümmendorf, Thomas Goddemeier

Invest New Drugs· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Ulrich Gatzemeier, Joachim von Pawel, Ihor Vynnychenko, Petr Zatloukal, Filippo de Marinis, Thomas Goddemeier

Lancet Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Robert Pirker, Jose R Pereira, Aleksandra Szczesna, Joachim von Pawel, Maciej Krzakowski, Thomas Goddemeier

Lancet· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simple-to-use, reference criteria for revealing drug-induced QT interval prolongation in conscious dogs.
Michael W Schmitt, Friedrich Von Landenberg, Hartmut Poth, Elmar Wimmer, Thomas Goddemeier

Eur J Pharmacol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis